SUSD2+ cancer-associated fibroblasts in gastric cancer mediate the effect of immunosuppression and predict overall survival and the effectiveness of neoadjuvant immunotherapy [0.03%]
胃癌中与癌症相关的SUSD2+成纤维细胞介导免疫抑制作用并可预测总生存期和新辅助免疫治疗的有效性
Rishun Su,Xuezeng Sun,Yusheng Luo et al.
Rishun Su et al.
Background: The expression patterns and functions of Sushi Domain Containing 2 (SUSD2) differ among various malignancies. This research aims to investigate the expression of SUSD2 and the role of the SUSD2+ cancer-associa...
Novel affibody molecules targeting the AXL extracellular structural domain for molecular imaging and targeted therapy of gastric cancer [0.03%]
针对AXL胞外结构域的新型Affibody分子用于胃癌分子影像和靶向治疗
HuiHui Zhang,Maolin Zheng,YiQi Cai et al.
HuiHui Zhang et al.
Gastric cancer (GC) has a poor prognosis and high mortality because it is often diagnosed at an advanced stage. Targeted therapeutics are considered an important class for advanced GC treatment. However, the fewer effective therapeutic targ...
Predicting chemotherapy responsiveness in gastric cancer through machine learning analysis of genome, immune, and neutrophil signatures [0.03%]
通过基因组、免疫和中性粒细胞特征的机器学习分析预测胃癌对化疗的反应性
Shota Sasagawa,Yoshitaka Honma,Xinxin Peng et al.
Shota Sasagawa et al.
Background: Gastric cancer is a major oncological challenge, ranking highly among causes of cancer-related mortality worldwide. This study was initiated to address the variability in patient responses to combination chemo...
Correction: Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study) [0.03%]
补遗：T-DXd在HER2阳性晚期胃癌日本患者中的疗效和安全性：EN-DEAVOR研究
Hisato Kawakami,Koki Nakanishi,Akitaka Makiyama et al.
Hisato Kawakami et al.
Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression [0.03%]
基于Claudin 18.2表达的第一线纳武利尤单抗联合化疗治疗胃癌患者的生存结果
Hyung-Don Kim,Jinho Shin,Jaewon Hyung et al.
Hyung-Don Kim et al.
Background: Claudin 18.2 has emerged as a viable therapeutic target in gastric cancer; however, its clinical relevance in the context of immune checkpoint inhibitor-based chemotherapy is not known. This study aimed to inv...
Short-term outcomes of a phase II trial of perioperative capecitabine plus oxaliplatin therapy for advanced gastric cancer with extensive lymph node metastases (OGSG1701) [0.03%]
术前卡培他滨联合奥沙利铂新辅助化疗治疗广泛淋巴结转移的局部晚期胃癌患者Ⅱ期临床研究短期结果分析
Yutaka Kimura,Naotoshi Sugimoto,Shunji Endo et al.
Yutaka Kimura et al.
Background: The prognosis of advanced gastric cancer (GC) with extensive lymph node (LN) metastasis treated with surgery alone remains poor. We conducted a multicenter phase II study to evaluate the efficacy and safety of...
Predictors of tolerability for postoperative adjuvant S1 plus docetaxel chemotherapy for gastric cancer: a multicenter retrospective study [0.03%]
围手术期S1联合多西他赛新辅助化疗耐受性影响因素的多中心回顾性研究
Kazuhiro Toyota,Kazuaki Tanabe,Mikihiro Kano et al.
Kazuhiro Toyota et al.
Background: Adjuvant docetaxel plus S1 (DS) chemotherapy after gastrectomy with D2 lymph node dissection is the standard treatment for stage III gastric cancer in Japan; however, some patients are unable to receive adequa...
Decorin as a key marker of desmoplastic cancer-associated fibroblasts mediating first-line immune checkpoint blockade resistance in metastatic gastric cancer [0.03%]
decorin作为介导转移性胃癌一线免疫检查点抑制剂耐药的间质细胞关键标志物
Ki Tae Kim,Min Hee Lee,Su-Jin Shin et al.
Ki Tae Kim et al.
Background: Gastric cancer (GC) remains a significant cause of cancer-related mortality worldwide. Despite the transformative impact of immune checkpoint blockade (ICB) therapies across various cancers, only a minority of...
Advantages of adjuvant chemotherapy using S-1 following minimally invasive gastrectomy for gastric cancer versus open surgery: a propensity score-matched analysis [0.03%]
腹腔镜胃癌手术后使用S-1辅助化疗相较于开放手术的益处：倾向性匹配分析
Motonari Ri,Naoki Nishie,Manabu Ohashi et al.
Motonari Ri et al.
Background: It is essential to ensure optimal adherence to adjuvant chemotherapy regimens following gastric cancer surgery. However, treatment intensity for S-1 as adjuvant chemotherapy has not as yet been compared betwee...
Morbidity and quality of life of totally laparoscopic versus laparoscopy-assisted distal gastrectomy for early gastric cancer: a multi-center prospective randomized controlled trial (CKLASS01) [0.03%]
全腹腔镜与手助腹腔镜远端胃癌切除术后生活质量及生存率的多中心随机对照研究(CKLASS01)
Yu Zhang,Ziyu Li,Yantao Tian et al.
Yu Zhang et al.
Background: There is a paucity of confirmatory randomized controlled trials (RCTs) comparing the effectiveness of totally laparoscopic distal gastrectomy (TLDG) vs laparoscopy-assisted distal gastrectomy (LADG) for early ...